Immune checkpoint inhibitors and drug-induced colitis

Immune checkpoint inhibitors and drug-induced colitis - Immune checkpoint inhibitors and drug-induced colitis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032854

Enrollment

Registered

2018-06-03

Start date

2018-06-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients who are going to administered immune checkpoint inhibitor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patient who is treated at Shiga Medical School Medical School affiliated hospital 2. Patient scheduled to receive an immunity checkpoint inhibitor 3. Age over 20 years old 4. Those who can acquire the consent of trial participation by voluntary intention from the principal in writing

Exclusion criteria

Exclusion criteria: 1. Patients who can not obtain consent 2. Patient undergoing antithrombotic therapy 3. When polyps that were judged to be resected for adaptation at the time of the initial colonoscopy are discovered 4. Patients with brachytherapy embedded for prostate cancer treatment

Design outcomes

Primary

Measure	Time frame
Endoscopic and microscopic colitis occurrence frequency at the sixth administration of immunity checkpoint inhibitor	—

Countries

Japan

Contacts

Public ContactShigeki Bamba

Shiga University of Medical Science Division of Clinical Nutrition

sb@belle.shiga-med.ac.jp0775482899

Outcome results